News | March 24, 2026
Japan okays new long-acting eye drug
It promises fewer injections for vision loss patients
It promises fewer injections for vision loss patients
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Subscribe To Our Newsletter & Stay Updated
